220 related articles for article (PubMed ID: 32369190)
1. COVID-19, chronic inflammatory respiratory diseases and eosinophils-Observations from reported clinical case series.
Jesenak M; Banovcin P; Diamant Z
Allergy; 2020 Jul; 75(7):1819-1822. PubMed ID: 32369190
[No Abstract] [Full Text] [Related]
2. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.
Tsioufis C; Dimitriadis K; Tousoulis D
Hellenic J Cardiol; 2020; 61(1):31-33. PubMed ID: 32450334
[No Abstract] [Full Text] [Related]
3. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.
Zhang JJ; Dong X; Cao YY; Yuan YD; Yang YB; Yan YQ; Akdis CA; Gao YD
Allergy; 2020 Jul; 75(7):1730-1741. PubMed ID: 32077115
[TBL] [Abstract][Full Text] [Related]
4. Oral submucous fibrosis and COVID-19: Perspective on comorbidity.
Sarode SC; Sarode GS; Gondivkar S; Gadbail A; Gopalakrishnan D; Patil S
Oral Oncol; 2020 Aug; 107():104811. PubMed ID: 32505551
[No Abstract] [Full Text] [Related]
5. Renin-angiotensin-aldosterone system and COVID-19 infection.
Alexandre J; Cracowski JL; Richard V; Bouhanick B;
Ann Endocrinol (Paris); 2020 Jun; 81(2-3):63-67. PubMed ID: 32370986
[TBL] [Abstract][Full Text] [Related]
6. Lifestyle and severe SARS-CoV-2 infections: Does the individual metabolic burden determines the outcome?
Markus B; Kreutz J; Schieffer B
J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320963929. PubMed ID: 33040679
[No Abstract] [Full Text] [Related]
7. Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.
Turgeon RD; Zieroth S; Bewick D; Chow CM; Clarke B; Cowan S; Fordyce CB; Fournier A; Gin K; Gupta A; Hardiman S; Jackson S; Lau B; Leong-Poi H; Mansour S; Marelli A; Quraishi AR; Roifman I; Ruel M; Sapp J; Singh G; Small G; Virani S; Wood DA; Krahn A
Can J Cardiol; 2020 Aug; 36(8):1180-1182. PubMed ID: 32502522
[No Abstract] [Full Text] [Related]
8. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.
Diaz JH
J Travel Med; 2020 May; 27(3):. PubMed ID: 32186711
[TBL] [Abstract][Full Text] [Related]
9. Diabetes mellitus: Lessons from the COVID-19 pandemic.
Tousoulis D
Hellenic J Cardiol; 2020; 61(1):1-2. PubMed ID: 32425483
[No Abstract] [Full Text] [Related]
10. Relative Limited Impact of COVID-19 on Diabetes: A Personal View.
de Galan BE
J Diabetes Sci Technol; 2020 Jul; 14(4):727-728. PubMed ID: 32468834
[No Abstract] [Full Text] [Related]
11. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
12. Intoxication With Endogenous Angiotensin II: A COVID-19 Hypothesis.
Sfera A; Osorio C; Jafri N; Diaz EL; Campo Maldonado JE
Front Immunol; 2020; 11():1472. PubMed ID: 32655579
[TBL] [Abstract][Full Text] [Related]
13. COVID-19: The heart of the issue.
Woodward B; Kermali M
J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
[No Abstract] [Full Text] [Related]
14. COVID-19 challenging cell biology.
Bullerdiek J
Protoplasma; 2020 May; 257(3):619-620. PubMed ID: 32333127
[No Abstract] [Full Text] [Related]
15. COVID-19 and the kidney.
Hassanein M; Radhakrishnan Y; Sedor J; Vachharajani T; Vachharajani VT; Augustine J; Demirjian S; Thomas G
Cleve Clin J Med; 2020 Oct; 87(10):619-631. PubMed ID: 33004323
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular disease and the impact of COVID-19.
Yoganathan A; Sajjad MS; Harky A
J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799
[No Abstract] [Full Text] [Related]
17. Are children less susceptible to COVID-19?
Lee PI; Hu YL; Chen PY; Huang YC; Hsueh PR
J Microbiol Immunol Infect; 2020 Jun; 53(3):371-372. PubMed ID: 32147409
[No Abstract] [Full Text] [Related]
18. Cardiovascular molecular mechanisms of disease with COVID-19.
Foo R; Wang Y; Zimmermann WH; Backs J; Wang DW
J Mol Cell Cardiol; 2020 Apr; 141():107. PubMed ID: 32289321
[No Abstract] [Full Text] [Related]
19. More evidence is urgently needed to confirm the relation between angiotensin-converting enzyme inhibitors and COVID-19.
Yang S; Meng G
J Mol Cell Cardiol; 2020 Apr; 141():110-111. PubMed ID: 32272142
[No Abstract] [Full Text] [Related]
20. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
Patel AB; Verma A
JAMA; 2020 May; 323(18):1769-1770. PubMed ID: 32208485
[No Abstract] [Full Text] [Related]
[Next] [New Search]
